Study: NCT05406999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg (250 mg×4 tablets) once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg (250 mg×4 tablets) once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone tablets
Description: 5 mg once daily, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone tablets
Description: 5 mg once daily, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg (40 mg× 4 tablets) once daily, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg (60 mg×4 tablets) once daily, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darotamide
Description: 600 mg (300 mg × 2 tablets) twice daily, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: 240 mg (80 mg × 3 tablets) once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor
Description: The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor
Description: The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.